42 completed, 13 terminated, 1 active not recruiting, 1 unknown. 58 Phase 1, 11 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 58 | Completed 42, Terminated 13, Active not recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 2 | 11 | Completed 7, Terminated 2, Active not recruiting 1, Unknown 1 |
Follow Leukemia, Erythroblastic, Acute: new trials by email Literature Review of Leukemia, Erythroblastic, Acute trials Research Report on Leukemia, Erythroblastic, Acute
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia Volasertib, Idarubicin, Cytarabine - Leukemia, Myeloid, Acute, Leukemia, Monocytic, Acute | Phase 1 | Withdrawn | University of Alberta | 2016-11-01 | 2017-04-05 | |
| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML metformin hydrochloride, cytarabine, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Northwestern University | 2 | 2015-03-11 | 2019-01-31 |
| MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia MEK inhibitor MEK162, idarubicin, cytarabine - Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Terminated | Bruno C. Medeiros | 1 | 2014-12-01 | 2017-12-06 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia lenalidomide, mitoxantrone hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Stanford University | 17 | 2014-02-01 | 2018-10-29 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies Aldesleukin, Allogeneic CD56-positive CD3-negative Natural Killer Cells, Allogeneic Hematopoietic Stem Cell Transplantation - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Erythroid Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 63 | 2013-06-11 | 2023-11-07 |
| Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia tretinoin, lithium carbonate, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Completed | Paolo Caimi, MD | 12 | 2013-04-30 | 2017-04-27 |
| Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia mitoxantrone hydrochloride, cytarabine, peripheral blood stem cell transplantation - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Terminated | University of Southern California | 10 | 2013-03-06 | 2018-03-30 |
| Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia azacitidine, cytarabine, mitoxantrone hydrochloride - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Completed | University of Chicago | 50 | 2012-06-06 | 2020-05-15 |
| Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia eltrombopag olamine, standard follow-up care - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Terminated | Roswell Park Cancer Institute | 10 | 2012-05-01 | 2022-07-22 |
| Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia trebananib, cytarabine, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Completed | Roswell Park Cancer Institute | 24 | 2011-10-31 | 2022-09-13 |
| Cyclosporine, Pravastatin Sodium, Etoposide, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia cyclosporine, pravastatin sodium, mitoxantrone hydrochloride - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 6 | 2011-04-01 | 2017-07-02 |
| Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia Azacitidine, Etoposide, Laboratory Biomarker Analysis - Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 13 | 2010-12-01 | 2015-08-20 |
| Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia cytarabine, etoposide, everolimus - Leukemia | Phase 1 | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 11 | 2010-10-01 | 2022-10-26 |
| Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia bortezomib, mitoxantrone hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Completed | Case Comprehensive Cancer Center | 3 | 2010-07-01 | 2015-08-13 |
| Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia entinostat, sorafenib tosylate, pharmacological study - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 44 | 2010-06-01 | 2013-09-19 |
| Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia cytarabine, clofarabine, filgrastim - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Completed | Nohla Therapeutics, Inc. | 29 | 2009-12-01 | 2019-03-01 |
| Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML vorinostat, gemtuzumab ozogamicin, azacitidine - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2009-05-01 | 2019-05-23 |
| Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia clofarabine, cytarabine, idarubicin - Leukemia, Myelodysplastic Syndromes | Phase 1 / Phase 2 | Unknown | European Organisation for Research and Treatment of Cancer - EORTC | 114 | 2008-11-01 | 2012-07-20 |
| Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia daunorubicin hydrochloride, cytarabine, bortezomib - Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 95 | 2008-09-01 | 2014-09-12 |
| Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders Carboplatin, Laboratory Biomarker Analysis, Topotecan Hydrochloride - Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2008-02-04 | 2025-04-02 |
Showing 20 of 58. Sign in to see all of them.
Leukemia, Myeloid, Acute (58) · Leukemia, Megakaryoblastic, Acute (56) · Leukemia, Monocytic, Acute (54) · Leukemia, Myelomonocytic, Acute (53) · Congenital Abnormalities (41) · Leukemia (25) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (24) · Leukemia, Basophilic, Acute (22) · Leukemia, Eosinophilic, Acute (22) · Blast Crisis (21) · Leukemia, Promyelocytic, Acute (14) · Leukemia, Myelomonocytic, Chronic (12) · Myelodysplastic Syndromes (12) · Leukemia, Myeloid, Accelerated Phase (11)
Bone Marrow Diseases (58) · Hematologic Diseases (58) · Hemic and Lymphatic Diseases (58) · Leukemia, Myeloid (58) · Neoplasms by Histologic Type (58) · Neoplasms (57) · Myeloproliferative Disorders (53) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (41) · Leukemia (33) · Disease Attributes (28) · Pathologic Processes (28) · Pathological Conditions, Signs and Symptoms (28) · Chronic Disease (27) · Immune System Diseases (24) · Immunoproliferative Disorders (24)
Cytarabine (26) · Etoposide (11) · Mitoxantrone (8) · Idarubicin (7) · Clofarabine (5) · Cyclophosphamide (5) · Daunorubicin (5) · Filgrastim (5) · fludarabine phosphate (5) · tipifarnib (5) · Azacitidine (4) · Bortezomib (4) · Busulfan (4) · Topotecan (4) · Peripheral Blood Stem Cell Transplantation (3)
National Cancer Institute (NCI) (22) · Case Comprehensive Cancer Center (4) · Roswell Park Cancer Institute (4) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Fred Hutchinson Cancer Center (2) · M.D. Anderson Cancer Center (2) · Bruno C. Medeiros (1) · Children's Oncology Group (1) · Daiichi Sankyo (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Memorial Sloan Kettering Cancer Center (1) · Nohla Therapeutics, Inc. (1) · Northwestern University (1)
United States (53) · Canada (4) · Italy (2) · Belgium (1) · Croatia (1) · France (1) · Georgia (1) · Netherlands (1)
Brenda W. Cooper, MD (2) · Jorge Cortes (2) · Joseph Brandwein, MD (2) · Judith E. Karp, MD (2) · Judith Karp (2) · Roland Walter (2) · Alex Adjei (1) · Anjali Advani (1) · Anjali Advani, MD (1) · Ann E. Woolfrey, MD (1) · Ann Mohrbacher (1) · B. Douglas Smith, MD (1) · B. Smith (1) · Bassem I. Razzouk, MD (1) · Bayard L. Powell, MD (1)
PMID 11331327, PMID 11585760, PMID 12750167, PMID 15514371, PMID 16275934, PMID 16670265, PMID 17562873, PMID 17640728, PMID 18571721, PMID 19010875, PMID 19092853, PMID 19109557, PMID 20460644, PMID 20952518, PMID 21239698, PMID 21791475, PMID 23256542, PMID 23443507, PMID 24002496, PMID 24142996, PMID 27374466, PMID 31375516, PMID 32074275, PMID 32211336, PMID 36184192
U01CA070095 (6), P30CA006973 (4), P30CA043703 (3), N01CM62204 (2), P30CA015704 (2), P30CA016056 (2), P30CA016672 (2), U01CA062491 (2), U01CA062505 (2), U01CA069912 (2), U01CA076576 (2), U10CA031946 (2), 2008 (1), N01CM00032 (1), N01CM17103 (1)